Aug 6 (Reuters) - Britain's Hikma Pharmaceuticals reported a 9% rise in half-year core-operating profit and maintained its ...

Trump plans to impose a 100% tariff on imported generic drugs in two years to bolster domestic manufacturing of these widely-used medications.

Trump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose ...

The latest tariff salvo underscored Trump's goal of reshoring low-cost drug production, but displacing established suppliers ...

Experts say that if Trump follows through, the proposed tariffs could have far-reaching consequences for the cost and ...

The White House said the policy will be implemented under Section 232 authority, giving drugmakers two years to shift generic drug production to the U.S. before tariffs rise.

Health policy experts say higher import duties could increase costs and strain supplies while offering no guarantee manufacturers will shift production to the U.S.

The president’s most recent tariff proposal gives pharma more time to transition its global supply chain and reshore generic ...

US President Donald Trump said on Tuesday he would impose tariffs on imported generic medicines from mid-2028 in a bid to ...

The U.S. will place a 100% tariff on generic pharmaceuticals starting in August 2028, President Trump posted on social media ...

With the popularity of glucagon-like peptide-1 (GLP-1) receptor agonists, many may find themselves turning to generic ...

More than 40 states and territories were involved in the settlement in principle with the generic drug manufacturer.